(Q33408501)

English

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

James Chung-Man Ho

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Jin Soo Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sumitra Thongprasert

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Li Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Guia Ladrera

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Vichien Srimuninnimit

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Virote Sriuranpong

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jennifer Sandoval-Tan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yunzhong Zhu

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Meilin Liao

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Caicun Zhou

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hongming Pan

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Victor Lee

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yuh-Min Chen

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yan Sun

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Benjamin Margono

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Fatima Fuerte

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gee-Chen Chang

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kasan Seetalarom

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jie Wang

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ashley Cheng

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Elisna Syahruddin

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xiaoping Qian

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Johan Kurnianda

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hsingjin Eugene Liu

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kate Jin

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Matt Truman

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ilze Bara

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

17 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

777-786

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Optimizing first-line treatment options for patients with advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70254-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33408501&oldid=1979087869"